• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Elacestrant: Treatment Considerations, Including Dosing and Compliance


Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure.

This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.

Mardones explores considerations for using oral selective estrogen receptor degraders (SERDs) with Callahan, Vidal, and Gradishar. Callahan highlights patients for whom she wouldn’t consider oral SERDs, emphasizing the need for alternatives in visceral crisis situations. Vidal discusses the recommended dose schedule, dose modifications, and potential adherence concerns, noting the convenience of oral therapy despite adherence challenges. Gradishar emphasizes the continuous and individualized treatment duration, which continues for as long as the patient responds and tolerates the therapy. Callahan sheds light on determining treatment failure, emphasizing the importance of definitive disease progression rather than relying solely on liquid biopsy results. The discussion provides insights into patient selection, dosing considerations, adherence challenges, and duration of treatment with oral SERDs, offering practical guidance for clinicians.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
Ronesh Sinha, MD
Yuqian Liu, PharmD
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"
dr monica li
dr lawrence eichenfield
Video 14 - "Achieving Equitable Representation in Clinical Studies"
Video 13 - "Measuring Implicit Bias"
Dr Michael Morse, Duke University
Video 10 - "Bronchiectasis Exacerbation Management"
Related Content
© 2024 MJH Life Sciences
All rights reserved.